Astellas Pharma (Japan)

Recent papers from Astellas Pharma (Japan)

1. Auditory oddball hypoactivation in schizophreniaPsychiatry Research Neuroimaging · 2023
2. Structural white matter abnormalities in Schizophrenia and associations with neurocognitive performance and symptom severityPsychiatry Research Neuroimaging · 2024
3. Integrated AI-Guided de novo CDR-H3 Design and Combinatorial Phage Display for Antibody DiscoveryAntibody Therapeutics · 2026
4. The patient’s perspective in the pharmaceutical regulatory and access pathway: considerations and recommendations from the 2025 Patient ForumGlobal & Regional Health Technology Assessment · 2026
5. A seamless dose-optimization design for monotherapy and combination therapyStatistical Methods in Medical Research · 2026
6. A new era of GPCR drug discovery: From receptor deorphanization to precision therapeuticsProceedings of the Japan Academy Series B · 2026
7. BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival EndpointPharmaceutical Statistics · 2026
8. A Bayesian Adaptive Design for Assessing Treatment Effect Consistency in Bridging StudiesStatistics in Medicine · 2026
9. Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysisESMO Open · 2026
10. Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodiesAntibody Therapeutics · 2026
11. Effect of fezolinetant on sleep, health-related quality of life and work productivityClimacteric · 2026
12. Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in JapanAdvances in Therapy · 2026
13. Multilevel Network Meta‐Regression With a Survival Outcome and an Application to Non‐Small Cell Lung CancerStatistics in Medicine · 2026
14. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitorCell Reports Medicine · 2026
15. A Cautionary Note on Regional Consistency Evaluation With Multiple Primary Endpoints in Multiregional Clinical TrialsPharmaceutical Statistics · 2026
16. Evaluating AI Performance in Systematic Literature Reviews for HEOR: A Case StudyJournal of health economics and outcomes research · 2026
17. Sustainable and Atom-Economical Continuous-Flow Synthesis of Iguratimod via Robust Heterogeneous N -Heterocyclic Carbene CatalysisACS Sustainable Chemistry & Engineering · 2026
18. Post‐Marketing Requirements for Anticancer Drugs Approved in Japan, 2001–2024: A Cross‐Sectional AnalysisCPT Pharmacometrics & Systems Pharmacology · 2026
19. Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in childrenAntimicrobial Agents and Chemotherapy · 2026
20. Intra-strain genomic microevolution and phage resistance in Pseudomonas aeruginosa PAO1 laboratory isolatesMicrobiology Spectrum · 2026